Lorlatinib 100 mg (Lorbrexen) is a highly effective targeted therapy for patients with ALK-positive non-small cell lung cancer. Learn more about these meds. Non-small cell lung cancer (NSCLC) is the most common type, accounting for 85% of all cases. Among patients with NSCLC, those diagnosed with ALK-positive tumors have a specific mutation in the anaplastic lymphoma kinase (ALK) gene. Lorlatinib, a medication designed to inhibit cancer cell growth and spread, can target this mutation. In this article, we will explore the benefits, side effects, and dosage of Lorlatinib 100 mg, effective treatment for ALK-positive NSCLC.